1208 EMB 4pm ET Rocket
BioCentury & Getty Images

Product Development

Latest data give Rocket clear path forward in rare CV disease Danon

Shares jump after-hours on better-than-expected efficacy despite SAE in high dose group

Dec 8, 2020 | 10:04 PM GMT

While an adverse event in the high-dose cohort continues to outline the limits of high volume AAV dosing,

Read the full 564 word article

How to gain access

Continue reading with a
two-week free trial.